Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

Titre officiel

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

Sommaire:

La coloscopie est actuellement la méthode de dépistage du cancer colorectal la plus avancée. Cependant, diverses raisons expliquent le très faible taux d’adhésion à cette méthode de dépistage chez la population. De nouveaux outils de dépistage sont nécessaires pour améliorer la détection du cancer du côlon. Des biomarqueurs fécaux, urinaires, sériques, tissulaires et plasmatiques peuvent constituer de précieux outils de dépistage initial permettant de classer la population en deux groupes : les personnes qui doivent passer une coloscopie et celles qui n’ont vraisemblablement pas besoin de passer un tel examen. Cette étude transversale est menée auprès de patients qui passent une coloscopie cliniquement indiquée ou qui ont reçu un diagnostic de cancer colorectal et qui sont disposés à fournir des échantillons biologiques.

Description de l'essai

Primary Outcome:

• Biospecimen Retention: Samples with DNA

In recognition of the fact that novel potential biomarkers are continually being identified and will need to be validated in a rapid, efficient and scientifically rigorous manner, the NCI has made an enormous commitment to the development of a network that will facilitate biomarker development and validation in multiple organ sites. As part of the National Cancer Institute-funded Early Detection Research Network (EDRN), the Great Lakes-New England Clinical Epidemiological Centre (GLNE CEC) proposes a research study that validates potential molecular markers ("biomarkers") for the detection of precancerous and cancerous conditions and cancer risk assessment. Although examples of such biomarkers are currently in clinical use (i.e. CEA, CA-125), there are limitations to all of them. Our consortium focuses on gastrointestinal neoplasia. The goals of this phase of the proposed research are: 1. Assessment of the utility of individual stool-based, serum-based and urine-based biomarkers for discriminating between patients with adenocarcinomas, patients with adenomas, patients without adenomas and normal subjects both at normal and high risk for developing colon cancer. 2. Construction of a panel of markers from those considered in Objective 1 to discriminate, under a number of assumptions concerning prevalence and cost of misclassification, between: 1. Subjects with normal colons versus patients without adenomas, patients with adenomas and patients with cancers; 2. Subjects with normal colons, patients without adenomas and patients with adenomas, versus subjects with cancers; 3. Subjects with normal colons versus patients without and patients with adenomas versus patients with cancers. 3. Comparison of the characteristics of individual markers and panels as discriminators to those of the established current standard, fecal immunochemical test (FIT). 4. Continued support of a renewal of a bank of stool samples linked to serum, tissue, and clinical data from patients with colorectal cancer, adenomas and normal controls for validation of stool-based markers that may be developed in the future. To build our collection, we propose to collect stool, FIT, serum, plasma, and tissue samples from 1200 new subjects. Each biomarker will be analyzed individually and considered as a potential panel marker to be used for future largescale screening longitudinal trials. (This protocol previously recruited an additional 682 subjects from January 2006 to June 2010.)

Voir cet essai sur ClinicalTrials.gov